The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia

Association, American Psychiatric

doi:10.1176/appi.books.9780890424841

Cited by 120 publications

(32 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, more than one third of Americans (36%) say that COVID-19 is having a serious impact on their mental health, according to a national poll by the American Psychiatric Association. 131 …”

Section: Adaptations In the Delivery Of Carementioning

confidence: 99%

Return to Work: Managing Employee Population Health During the COVID-19 Pandemic

Fragala

Goldberg

2021

Population Health Management

View full text Add to dashboard Cite

Coronavirus disease-2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has abruptly transformed the outlook of employer health benefits plans for 2020 and 2021. Containing the spread of the virus and facilitating care of those infected have quickly emerged as immediate priorities. Employers have adjusted health benefits coverage to make COVID-19 testing and treatment accessible and remove barriers to care in order to facilitate the containment of the disease. Employers also are introducing strategies focused on testing, surveillance, workplace modifications, and hygiene to keep workforces healthy and workplaces safe. This paper is intended to provide evidence-based perspectives for self-insured employers for managing population health during the COVID-19 pandemic. Such considerations include (1) return to work practices focused on mitigating the spread of COVID-19 through safety practices, testing and surveillance; and (2) anticipating the impact of COVID-19 on health benefits and costs (including adaptations in delivery of care, social and behavioral health needs, and managing interrupted care for chronic conditions).

show abstract

Section: Adaptations In the Delivery Of Carementioning

confidence: 99%

Return to Work: Managing Employee Population Health During the COVID-19 Pandemic

Fragala

Goldberg

2021

Population Health Management

View full text Add to dashboard Cite

show abstract

“…Based on a recent update of a Cochrane review on Intensive Care Management (ICM), the Royal Australian and New Zealand College of psychiatrists recommend a team based clinical setting to manage schizophrenia and related disorders [39,40]. The 15th statement of the recent update of the American Psychiatric Association recommends Coordinated Specialty Care programs to manage schizophrenia, and especially the first episode of psychosis [41].…”

Section: Team-based Models Of Care Must Include Pharmacistsmentioning

confidence: 99%

Clinical Pharmacy in Psychiatry: Towards Promoting Clinical Expertise in Psychopharmacology

et al. 2021

View full text Add to dashboard Cite

Although clinical pharmacy is a discipline that emerged in the 1960s, the question of precisely how pharmacists can play a role in therapeutic optimization remains unanswered. In the field of mental health, psychiatric pharmacists are increasingly involved in medication reconciliation and therapeutic patient education (or psychoeducation) to improve medication management and enhance medication adherence, respectively. However, psychiatric pharmacists must now assume a growing role in team-based models of care and engage in shared expertise in psychopharmacology in order to truly invest in therapeutic optimization of psychotropics. The increased skills in psychopharmacology and expertise in psychotherapeutic drug monitoring can contribute to future strengthening of the partnership between psychiatrists and psychiatric pharmacists. We propose a narrative review of the literature in order to show the relevance of a clinical pharmacist specializing in psychiatry. With this in mind, herein we will address: (i) briefly, the areas considered the basis of the deployment of clinical pharmacy in mental health, with medication reconciliation, therapeutic education of the patient, as well as the growing involvement of clinical pharmacists in the multidisciplinary reflection on pharmacotherapeutic decisions; (ii) in more depth, we present data concerning the use of therapeutic drug monitoring and shared expertise in psychopharmacology between psychiatric pharmacists and psychiatrists. These last two points are currently in full development in France through the deployment of Resource and Expertise Centers in PsychoPharmacology (CREPP in French).

show abstract

“…Guidelines and recommendations have been released by the American Psychiatric Association (APA), individual states, and other countries and organizations to improve both quality of care and treatment outcomes in patients with schizophrenia [24][25][26][27][28]. Although these documents tend to have general consistencies, recommendations beyond firstline treatment are unclear, and the amount of published literature in this area is limited.…”

Section: Introductionmentioning

confidence: 99%

Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia

et al. 2021

View full text Add to dashboard Cite

Schizophrenia is a serious mental illness that requires continuous and effective long-term management to reduce symptoms, improve quality of life, and prevent relapse. Oral antipsychotic medications have proven efficacy for many patients taking these medications; however, a considerable number of patients continue to experience ongoing symptoms and relapse, often due to lack of adherence. The advent of long-acting injectable (LAI) formulations of antipsychotic medications provided an opportunity to improve treatment adherence and overall patient outcomes. Despite data to support LAI efficacy, safety, and improved adherence over oral formulations, there are several misconceptions about and barriers to LAI implementation within a standard of care for patients with schizophrenia. Areas of resistance around LAIs include (1) doubts regarding their benefits outside of improved adherence, (2) questions regarding their prescribing to a broader population of patients with schizophrenia, (3) when to initiate LAIs, (4) concerns regarding the safety of LAIs in comparison with oral medication, and (5) the most effective ways to educate healthcare providers, patients, and caretakers to enable appropriate LAI consideration and acceptance. Here, we discuss these key controversies associated with LAIs and provide supportive evidence to facilitate LAI use in a manner that is constructive to the clinician-patient relationship and successful treatment. Plain Language SummarySchizophrenia is a mental condition that affects how a person acts, thinks, sees, and interprets their surroundings and expresses how they feel. Relapse can lead to hospitalization and other poor outcomes. Almost half of patients with schizophrenia tend to start and stop treatment, which can cause more relapses and make symptoms worse over time. Using antipsychotic drugs long term can reduce impairing illness symptoms and improve patient quality of life. Consistent use of antipsychotic drugs can help prevent relapse. Available antipsychotic drugs can be taken by mouth (oral) or by an injection. Oral drugs have to be taken every day, whereas long-acting injections (LAIs) of antipsychotic drugs can be given less often, such as every 2 weeks, monthly, and up to once every 3 months. In the past, LAIs were used only when oral antipsychotic drugs did not work, which was usually because patients did not take them every day. However, LAIs also work as an early treatment, which can be better for the patient. Patients taking LAIs skip fewer doses and so may have fewer relapses and hospitalizations. Because LAIs have to be given at the clinic, patients get more regular medical care and tend to keep taking their medicine for longer. Most LAI side effects are similar to those of oral antipsychotic drugs. Despite this, some clinicians hesitate to prescribe LAIs. More education for clinicians and patients about LAIs could increase interest and use. Recovery and relapse prevention are the main treatment goals for patients and their care team, and LAIs can improve both.

show abstract

The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia

Cited by 120 publications

References 0 publications

Return to Work: Managing Employee Population Health During the COVID-19 Pandemic

Return to Work: Managing Employee Population Health During the COVID-19 Pandemic

Clinical Pharmacy in Psychiatry: Towards Promoting Clinical Expertise in Psychopharmacology

Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia

Contact Info

Product

Resources

About